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In June 2001, dengue transmission was detected in
Havana, Cuba; 12,889 cases were reported. Dengue 3, the
etiologic agent of the epidemic, caused the dengue hemor-
rhagic fever only in adults, with 78 cases and 3 deaths.
After intensive vector control efforts, no new cases have
been detected. 
I
n 1994, after 17 years of absence, Nicaragua, Panama,
and Costa Rica reported the reintroduction of dengue 3
virus in the region (1,2). The last isolation of this serotype
occurred in 1977–1978 in Puerto Rico and Colombia (1,2).
Dengue 3 has been related to dengue fever (DF) and
dengue hemorrhagic fever (DHF) epidemics. In 7 years the
virus has disseminated first to Central-American countries,
and later to Mexico, Caribbean countries, and more recent-
ly, to South America (3). This virus is genetically different
from the dengue 3 strain previously isolated in the
Americas and belongs to the same genotype as the virus
that caused DHF epidemics in Sri Lanka and India (sub-
type III) (4). Currently, it is believed that millions of per-
sons in the American region are at risk of dengue 3
infection.
Previously, larger epidemics in Cuba were associated
with dengue 1 in 1977 and with dengue 2 in 1981. Both
epidemics affected the entire country, producing more than
500,000 and 300,000 dengue cases, respectively. More
than 10,000 cases of DHF causing 158 deaths were report-
ed in 1981. From 1982 to 1996, no dengue transmission
was reported. In 1997, a dengue 2 epidemic was reported
in the municipality of Santiago de Cuba, located in the
eastern part of the country (5). In September 2000, a small
outbreak of dengue was detected in Havana City; 138
cases of dengue fever (DF) were confirmed at that time,
and both dengue 4 and dengue 3 viruses were isolated; the
outbreak ended by December (6,7).
The Study
Havana is the capital city of the Republic of Cuba with
15 municipalities, 2,193,848 inhabitants, and a population
density of 3,040/km2. Located in the north of the country,
it covers an area of 720.84 km2 and has an annual average
temperature of 25°C. La Habana province surrounds
Havana City on the east, west, and south. House indexes
(percentage of houses with at least one infested container)
of 0.05 to 0.91 were reported from 1997 to 2001. In July
2001, house indexes at the municipalities of the city varied
from 0.2 to 1.5; however, higher figures were observed at
health areas and blocks. These data demonstrate that trans-
mission risk must be assessed in more numerous, smaller
geographic areas. The entomologic surveillance and vector
control activities involved 4,796 workers; 3,278 family
doctors’ offices (one family doctor per 120 families and
600 inhabitants) and 81 health areas constitute the primary
health care system, and 23 hospitals comprise the second
and third levels.
Once the Santiago de Cuba epidemic was detected in
January 1997 (5,8,9), an active dengue surveillance system
was established throughout the country. Specifically in
Havana City, the surveillance was directed at detecting
dengue transmission by studying patients with undifferen-
tiated fever and patients with suspected dengue (patients
with fever and two or more symptoms of DF such as myal-
gia, arthralgia, headache, and rash). 
A serum sample for dengue immunoglobulin (Ig) M
detection was collected 5 days after onset of fever. IgM
studies were conducted first at the laboratory of the Centro
Provincial de Higiene y Epidemiologia de Ciudad Habana
(CPHE-CH) by using the ultramicro-enzyme-linked
immunosorbent assay (µM ELISA) for dengue IgM detec-
tion (10). Positive samples were confirmed at the national
reference center, the Tropical Medicine Institute (IPK) by
an IgM capture ELISA (11). A comprehensive study from
clinical, epidemiologic, and entomologic perspectives was
conducted at those health areas where case-patients were
found; a second serum sample was collected 2–3 weeks
after illness onset to demonstrate the antibody seroconver-
sion or a fourfold increase in antibody titer (12). The Table
shows the total number of serum samples studied from
1997 to 2002. 
In June 29, 2001, a confirmed dengue case was reported
to the national health authorities. The index case had an
onset date of June 16. The index case-patient was a 68-year-
old white woman who lived in the “26 de Julio” health area
of the Playa municipality; she had no history of travel out-
side the country. The “26 de Julio” health area was a resi-
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received water every 2 days). The house index was 2.1.
Many persons from dengue-endemic countries lived in the
area, and many boarding houses also characterized this area.
Within 2 weeks, 20 additional DF cases were serologi-
cally confirmed. A retrospective seroepidemiologic study
was conducted in a radius of 1 km2 around the index
patient to look for any patients with suspected dengue or
undifferentiated fever; 312 febrile patients, and 14 suspect-
ed DF patients were found; however, DF was confirmed by
serologic studies in 4 of them. All 4 case-patients had
dengue IgM and high titers of IgG dengue antibodies.
Epidemiologic studies of these patients showed that the
first case occurred in late May or early June. The primary
case-patient was a 53-year-old white man from the same
health area as the index patient. 
Once transmission was confirmed, a proactive dengue
surveillance program was established, based on informa-
tion from family doctors. Virologic and molecular surveil-
lance demonstrated that dengue 3 was the etiologic agent
of the epidemic. Ninety-one dengue 3 isolates were
obtained from samples collected at various times during
the epidemic. 
Considering the active surveillance and that specimens
from all identified clinical case-patients were studied by
serologic or virologic methods, the figure of confirmed
cases is very close to the total number of dengue clinical
cases of the epidemic. All confirmed case-patients were
notified. Figure 1 shows the histogram of the epidemic,
and Figure 2 shows the municipality distribution and the
date of confirmed transmission in the city. By week 30
(July) new cases were detected in the Arroyo Naranjo
Municipality, and by the end of October (week 42), almost
all municipalities had reported dengue transmission. 
The wide clinical spectrum of dengue was established
in the Pan American Health Organization (PAHO)/World
Health Organization (WHO) guidelines (13). Because of
the detection of dengue transmission in the city, the exis-
tence of the primary health system, and the strong dengue
surveillance system that included laboratories with appro-
priate technology for serologic diagnosis, we decided to
extend the clinical, epidemiologic, and laboratory surveil-
lance to the study of almost all undifferentiated fever cases
and those patients with a compatible classic dengue pic-
ture. Ahouse-by-house survey for febrile cases and dengue
suspected cases was performed in Havana City by the fam-
ily doctors. As a result, 72,162 cases (41,830 undifferenti-
ated fever and 30,332 dengue suspected cases) were
epidemiologically, clinically, and serologically studied.
Dengue infection was confirmed in 12,889 (17.86%) of the
total cases. Of patients with confirmed cases, 1,660
(12.9%) were children and 11,229 were adults (87.1%);
52.4% were female and 47.6% were male. DHF was diag-
nosed in 78 patients, all adults (16–64 years of age). The
main signs and symptoms detected in patients with con-
firmed dengue cases at the time of hospital admission were
fever, 100%; headache, 89%; retrorbital pain, 59.2%;
arthralgia, 59.4%; myalgia, 35.2%; and rash, 28.1%. Other
symptoms such as cough, diarrhea, nausea, and vomiting
were observed in 21.2% of case-patients. 
The peak of the epidemic occurred in October and the
highest number of cases occurred on October 20 (241
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Table. Total serum samples from Havana City analyzed at both 
the provincial (CPHE-CH) and national level (IPK), 1999–2002
a 
Y  CPHE-CH  IPK 
1997  807  9,538 
1998  1,377  4,794 
1999  4,166  10,012 
2000  39,335  19,752 
2001  65,770  38,513 
2002
b  11,302  13,304 
Total  122,757  95,913 
aCPHE-CH,Centro Provincial de Higiene y Epidemiologia de Ciudad Habana; 
IPK, Tropical Medicine Institute. 
bThrough March 2002. 
Figure 1. Dengue confirmed case notification according to onset of
fever.
Figure 2. Extension of the epidemic in Havana City, 2001-2002confirmed cases); 1,150 cases were confirmed by week 42
(October 14–20). 
The onset of symptoms of the last two case-patients
occurred by February 22, 2002. The epidemic was consid-
ered controlled 36 days later with confirmation that no
possibility of transmission existed. Case fatality rate was
3.8% among patients with DHF/dengue shock syndrome
(DSS). Mortality rate was 0.13/100,000 inhabitants and
morbidity rate was 59.2/ 10,000 inhabitants. 
Conclusions
After the first cases were detected, all patients with sus-
pected dengue and those who were severely ill, or those
classified as having DHF/DSS were hospitalized, all adults
at the IPK hospital and all children at the Aballi and Cerro
Pediatric Hospitals. In total, 4,184 patients were hospital-
ized, 3,197 adults and 987 children. By the end of the epi-
demic in January 2002, a broad hospitalization policy was
established in areas free of vector, Aedes aegpyti mosqui-
toes, (all febrile and dengue suspected case-patients were
hospitalized or treated at home with daily visits by the
family doctor). (13). Anatomopathologic and histopatho-
logic studies were conducted in all fatal cases.
The vector control strategy had two phases: the first
started as soon as the transmission was detected and
restricted the number of cases and geographic extension of
the epidemic (the risk of expansion of the epidemic was
high because of the vector indexes in Havana City and
other provinces).The second phase, called the Intensive
Campaign, started at the beginning of January 2002 and
interrupted transmission and, consequently, lowered the
risk of dengue endemicity in approximately 70 days. The
Campaign was based on the principles of dengue control
established by the PAHO Guidelines (13) with the involve-
ment of the whole community (the head of state, govern-
mental and political bodies at all levels, householders,
community organizations, etc.). The objectives of the
Intensive Campaign were to control the vector and inter-
rupt dengue transmission. Massive environmental manage-
ment and sanitation efforts, the elimination of breeding
sites, and the elimination of adult mosquitoes were also
carried out. These activities were accompanied by exten-
sive efforts to mobilize the community, a strong program
of quality control, the active media involvement, and the
repositioning of tanks and different water containers. From
a house index of 0.49 at the beginning of the Intensive
Campaign, this figure diminished to 0.01 by March 4. The
intensive active surveillance and the hospitalization of all
febrile patients and all patients thought to be infected with
dengue were crucial in order to reduce the dengue trans-
mission.
At present, after 17 months since the last dengue case,
strong surveillance is maintained by the six regional labo-
ratories and the national reference center, and no addition-
al cases have been reported. These data indicate that
endemicity was avoided. Efforts are being made to elimi-
nate Ae. aegpyti in a regional situation in which the disease
has caused unprecedented numbers of cases of DF and
DHF (1,015,420 dengue cases and 14374 dengue hemor-
rhagic fever, with 225 deaths have been reported to PAHO)
(data provided by Jorge Arias, WHO American regional
office). As has been stated in the PAHO resolution
approved by the PanAmerican Health Assembly in
September 2002 (14), a concerted action at a regional level
is urgently needed. 
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